Kyverna Therapeutics (NASDAQ:KYTX) and Zhengye Biotechnology (NASDAQ:ZYBT) Critical Contrast

Zhengye Biotechnology (NASDAQ:ZYBT) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Zhengye Biotechnology and Kyverna Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$153.74 million	0.23	$1.55 million	N/A	N/A
Kyverna Therapeutics	N/A	N/A	-$127.48 million	($3.73)	-2.17

Zhengye Biotechnology has higher revenue and earnings than Kyverna Therapeutics.

Insider and Institutional Ownership

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 22.0% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Zhengye Biotechnology and Kyverna Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1	0	0	0	1.00
Kyverna Therapeutics	1	0	4	0	2.60

Kyverna Therapeutics has a consensus target price of $28.67, suggesting a potential upside of 253.91%. Given Kyverna Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Zhengye Biotechnology.

Volatility and Risk

Zhengye Biotechnology has a beta of -4.21, meaning that its share price is 521% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.32, meaning that its share price is 232% more volatile than the S&P 500.

Profitability

This table compares Zhengye Biotechnology and Kyverna Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Kyverna Therapeutics	N/A	-77.94%	-65.83%

Summary

Kyverna Therapeutics beats Zhengye Biotechnology on 6 of the 10 factors compared between the two stocks.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.